Compare Figs Inc (FIGS) vs Cassava Sciences Inc (FLNA) Price & Performance

FIGS trades at $9.72, down 2.8% today, amid bearish technical signals despite recent earnings beats. Revenue grew to $631M in 2025 with a 66.6% gross margin, but net cash flow remains negative. Analyst consensus is bullish with a $19.50 price target, though technical indicators show selling pressure with RSI at neutral levels and ADX signaling a strong downtrend.

The stock presents a growth opportunity with strong fundamentals and analyst support, but faces near-term technical headwinds and margin pressures from tariffs and freight costs. Investors should weigh the 100% upside to consensus target against execution risks and persistent negative cash flow trends.

Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.

The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.